Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.

Phase 3

Completed

Conditions: Primary Hyperparathyroidism
Parathyroid Adenoma
Parathyroid Hyperplasia

Interventions: Drug: Cinacalcet 30 mg Tablet
Drug: Denosumab Inj 60 mg/ml
Other: Placebo tablets
Other: Saline Injection (Placebo)

Registration Number: NCT03027557

Lead Sponsor: Peter Vestergaard

Brief Summary: The only known cure for primary hyperparathyroidism is surgical removal of one or more parathyroid glands. Some patients however, do not fulfill criteria for surgery or do not want to undergo a procedure due to fear of the associated risks. Therefore a medical alternative is warranted.

This study aims to evaluate the effects of Denosumab alone, and in combination with Cinacalcet, as a medical treatment for patients suffering from primary hyperparathyroidism, with mild osteoporosis. To the best of our knowledge no previously reported randomized controlled trial has investigated the use of denosumab in primary hyperparathyroidism.

60 patients will be enrolled in three different treatment-groups: 20 receiving both Denosumab and Cinacalcet, 20 Denosumab and placebo and 20 placebo and placebo. Patients included do not meet the criteria for, or have no wish for a surgical procedure.

By combining the two drugs, this study could possibly contribute to the discovery of a realistic medical alternative to surgery. It is expected that the therapy will be able to both control s-calcium and s-intact parathyroid hormone (iPTH), and simultaneously enhance bone-structure. The therapy thus has the potential of preventing fractures and possibly other long-term effects of primary hyperparathyroidism such as formation of kidney stones, and coronary calcification. Another objective of this project is to investigate whether the combined therapy can facilitate an actual reset of the Calcium-sensing receptor, and thereby de facto cure the disease.

Detailed Description: Background/Context:

This project deals with medical treatment of primary hyperparathyroidism. The only cure currently available is surgical removal of one or more parathyroid glands, but this option is neither feasible, nor desirable in all patients with the diagnosis.

Today a major group of patients are being diagnosed by coincidence with biochemical blood-screening, and are therefore in an asymptomatic state of the disease at the time of diagnosis. Long term studies show that these patients over time often have progression in their disease, and develop complications such as osteoporosis. Thus a medical alternative is warranted.

Previous studies have investigated the effects of well known antiresorptive drugs such as bisphosphonates, as well as estrogen-related compounds. These drugs have had effects on particularly bone mineral density (BMD) and biochemical bone-turnover markers, but have been able only transiently to lower blood-calcium levels. Combined with too many unwanted side-effects and a high prevalence of contraindications for a large proportion of the patients needing treatment, these drugs have not provided a realistic alternative to surgery.

Treatment today generally follows the international consensus for treatment of asymptomatic patients with primary hyperparathyroidism. Briefly this includes watchful waiting with biannual control-sessions for indication of surgery, screening for kidney stones/nephrolithiasis, osteoporosis and s-calcium - and s-iPTH levels.

This randomized controlled trial involves the drugs Cinacalcet og Denosumab. Denosumab has previously been shown to greatly improve BMD, lower s-calcium, lower the rate of bone-turnover and prevent osteoporotic fractures in several populations with different diseases, but has never been tested in a published randomized controlled trial in patients with primary hyperparathyroidism.

Cinacalcet has been proved able to lower s-iPTH, lower s-Calcium and thereby relieve symptoms of hypercalcaemia caused by primary hyperparathyroidism. It does not however, lower the rate of bone turnover, and it has not been show to improve BMD.

By combining the two drugs, this study could possibly contribute to the discovery of a realistic medical alternative to surgery. It is expected that the therapy will be able to both control s-calcium and s-iPTH, and simultaneously enhance bone-structure. The therapy thus has the potential of preventing fractures and possibly other long-term effects of primary hyperparathyroidism such as formation of kidney stones, and coronary calcification. Another objective of this project is to investigate whether the combined therapy can facilitate an actual reset of the Calcium-sensing receptor, and thereby de facto cure the disease.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 46

Inclusion Criteria

Men and women of 18 years of age or older.
T-score by Dual X-ray Absorptiometry (DXA) between -1,0 og -3,5
Patients from The North Jutland Region diagnosed with primary hyperparathyroidism at the Department of Endocrinology, Aalborg University Hospital. (Hypercalcaemia measured at two different time-points and simultaneous elevated/inappropriately high PTH, and exclusion of differential diagnosis.)

Exclusion Criteria

Medical history of diseases leading to hypercalcaemia other than Primary Hyperparathyroidism.
Patients being treated with Denosumab or Cinacalcet prior to inclusion or previously treated with Denosumab or Cinacalcet.
Moderately - Severely decreased liver function (alanine aminotransferase >250u/l, gamma-glutamyl transferase>150u/l, Bilirubin >30)
Acute myocardial infarction or apoplexia in the 3 months before inclusion.
Medical record of heart failure
Risk factors of prolonged corrected QT interval (QTc).
Open lesions from oral surgery.
Primary diseases of the bone other than osteoporosis.
Patients suffering from kidney disease or renal failure.
Patients under treatment with thiazide or lithium.
Medical record of generalized seizures or epilepsy.
Active malignant disease.
Known allergies towards the specified medicinal products (IMPs).
Pregnancy or breastfeeding.
Fertile women who do not agree to the usage of effective contraception.
Other circumstances, evaluated by the responsible investigator, making the subject unsuitable for participation.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Combined treatment.	Cinacalcet 30 mg Tablet	20 subjects will be treated with combined 60mg denosumab bi-annually , 30 mg cinacalcet daily and 50 micrograms vitamin-D daily.
Combined treatment.	Denosumab Inj 60 mg/ml	20 subjects will be treated with combined 60mg denosumab bi-annually , 30 mg cinacalcet daily and 50 micrograms vitamin-D daily.
Monotherapy	Denosumab Inj 60 mg/ml	20 subjects will receive 60mg denosumab bi-annually, placebo and 50 micrograms vitamin-D daily.
Monotherapy	Placebo tablets	20 subjects will receive 60mg denosumab bi-annually, placebo and 50 micrograms vitamin-D daily.
Placebo	Placebo tablets	20 subjects will receive a saline injection bi-annually (blinded), placebo-tablets and 50 micrograms vitamin-D daily.
Placebo	Saline Injection (Placebo)	20 subjects will receive a saline injection bi-annually (blinded), placebo-tablets and 50 micrograms vitamin-D daily.

Primary Outcome Measures

Name	Time	Method
Change in Total Hip Bone Mineral Density	Baseline,one year	Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.
Change in Femoral Neck Bone Mineral Density	Baseline,one year	Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.
Percentage Change in Lumbar Spine Bone Mineral Density	Baseline,one year	Percentage change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.
Percentage Change in Total Hip Bone Mineral Density	Baseline,one year	Percentage change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.
Percentage Change in 1/3 Forearm Bone Mineral Density	Baseline,one year	Percentage change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.
Change in Lumbar Spine Bone Mineral Density	Baseline,one year	Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.
Change in 1/3 Forearm Bone Mineral Density	Baseline,one year	Change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.
Percentage Change in Femoral Neck Bone Mineral Density	Baseline,one year	Percentage change of Bone Mineral Density after one year of treatment from baseline. Measured with Dual-energy X-ray absorptiometry (DXA)-scan.

Secondary Outcome Measures

Name	Time	Method
Percent Change From Baseline in P-carboxy-terminal Collagen Crosslinks (CTX)	Change from baseline at 48 weeks reported.	p-CTX, change from baseline at 48 weeks.
Change MDI-score	Baseline, 6 mths, one year.	Major Depression Inventory (MDI)-score, Baseline, 6 months, one year (week 52)., change between baseline and 1 year reported. The Major Depression Inventory (MDI) is a mood questionnaire developed by the World Health Organization. To calculate the total score, a sum of ten individual items (each with an individual score between 0-5, with 0 indicating absence of a symptom and 5 indicating constant presence of a given symptom) is used. A higher score signifies deeper depression with 50 being the maximum score.
Bone Mineral Content	Baseline, one year	Measured at baseline and after one year at the lumbar spine and distal 1/3 of the non-dominant antebrachii.
Percentage Change in Volumetric BMD for the Lumbar Spine.	Baseline, one year	Measured at baseline and after one year by QCT.
Change in Volumetric BMD for the Lumbar Spine.	Baseline, one year	Measured at baseline and after one year by QCT.
Vertebral Fracture Assessment - Final Scan	Patients with vertebral fractures at one year reported.	Number of participants with vertebral fractures as assessed by VFA at final scan.
Change in Cortical Width.	Baseline, one year.	Measured at baseline and after one year at the distal non-dominant antebrachii.
Mean P-calcium During Treatment.	Monthly up to one year.	Blood samples were acquired once every 4 weeks for safety-purposes.
Patients With Nephrolithiasis Final Scan.	Patients with nephrolithiasis at one year reported.	Number of subjects w. renal stones at final scan.
Change in Volumetric BMD for the Distal Forearm.	Baseline, one year	Measured at baseline and after one year by QCT.
Median Agatstons Score Final	Baseline, one year	Simultaneously with QCT-measurements coronary calcification was be assessed. Agatston score is a score based on the extent of coronary artery calcification calculated on the amount of plaque observed in a CT scan. A score of zero indicates absence of coronary calcium, 1-10: minimal calcification, 11-100 mild calcification, 101-400 moderate calcification, \>400 severe calcification. Thus the score increases with increasing level of calcification in the coronary vessels.
Reset of the Calcium Sensing Receptor?	2 weeks after termination of medication.	Measured from effect on s-calcium and PTH weeks after termination of IMP
Adverse Reactions.	Monthly up to one year.	All participants filled in questionnaires regarding symptoms related to the treatment. Results are reported in the Adverse Events section.
Patients With Pancreas-calcifications Final Scan.	Patients with pancreas-calcifications at one year reported.	By QCT.
Mean p-PTH During Treatment.	Monthly up to one year.	Blood samples were acquired once every 4 weeks for safety-purposes.
Mean p-Phosphate During Treatment.	Monthly up to one year.	Blood samples were acquired once every 4 weeks for safety-purposes.
Percent Change From Baseline in p-N-terminal Propeptide of Type I Procollagen (p-P1NP).	Change from baseline at 48 weeks reported.	p-P1NP, change from baseline at 48 weeks.
Percentage Change in Volumetric BMD for the Distal Forearm.	Baseline, one year	Measured at baseline and after one year by QCT.
Percent Change From Baseline in P-osteocalcin.	Change from baseline at 48 weeks reported.	p-osteocalcin, change from baseline at 48 weeks.
Percent Change From Baseline in S-bone-specific Alkaline Phosphatase (BAP).	Change from baseline at 48 weeks reported.	S-Bone specific alkaline phosphatase, change from baseline at 48 weeks.
Percent Change From Baseline in p-Tartrate-resistant Acid Phosphatase 5b (Trap5b).	Change from baseline at 48 weeks reported.	P-Trap5b, change from baseline at 48 weeks.
Percent Change From Baseline in p-Sclerostin.	Change from baseline at 48 weeks reported.	P-Sclerostin, change from baseline at 48 weeks.
Percent Change From Baseline in P-fibroblast Growth Factor 23 (FGF23).	Change from baseline at 48 weeks reported.	P-FGF23 , change from baseline at 48 weeks.
Changes in p-25-vitamin D	Change from baseline at 48 weeks reported.	P-25-vitD , change from baseline at 48 weeks.
Changes in s-1,25-vitamin D	Change from baseline at 48 weeks reported.	S-1,25-vitD, change from baseline at 48 weeks.
Patients With Nephrocalcinosis, Final Scan.	Baseline, one year	Number of subjects w. renal calcifications at final scan.